Adding the lutetium-labelled PSMA*-617 (177Lu PSMA-617) targeted radioligand therapy to standard of care (SOC) led to significant extension of radiographic progression-free survival (rPFS) and overall survival (OS) compared with SOC alone in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed after treatment with chemotherapy and androgen inhibitors, according to the VISION trial presented at ASCO 2021.
Use of the angiotensin receptor blocker (ARB) candesartan in the treatment of COVID-19 appears to shorten hospital stay overall, as well as speed up lung injury resolution and viral clearance for patients without obesity, according to the results of a study from Indonesia.
Supplementation with cholecalciferol or calcifediol to improve vitamin D status can lead to large, population-wide improvements in outcomes of the novel coronavirus disease (COVID-19), a recent study has found.
Long-term care facility (LTCF) residents aged ≥65 years appeared to be protected from COVID-19 4–7 weeks after receiving their first dose of the ChAdOx1 nCoV-19 or BNT162b2 vaccine, according to a study presented at ECCMID 2021.
People with migraine were more likely to report having COVID-19 symptoms, yet less likely to utilize healthcare resources compared with infected individuals without migraine, according to a study presented at the 2021 AHS Annual Meeting.
In hospitals, the risk of acquiring methicillin-resistant Staphylococcus aureus (MRSA) is high in wards that receive a high number of MRSA-colonized patients coming from other wards, according to a Singapore study.
Patients with psoriasis taking the immunosuppressant methotrexate had low antibody responses to SARS-CoV-2 after receiving the first dose of Pfizer-BioNTech’s BNT162b2 vaccine but had shown T-cell responses, according to a study that was the first to look at T-cell responses in patients taking methotrexate.